Conclusion:IA results for the China cohort of the VISIONARY trial were consistent with those previously observed in the IA of the global main cohort.Treatment with sibeprenlimab was associated with clinically meaningful reductions in proteinuria and biomarkers in patients with IgAN.Safety findings were comparable to placebo.Safety and the key secondary efficacy endpoint (eGFR slope) will be assessed at 24 months.I have potential conflict of interest to disclose.
Ng et al. (Wed,) studied this question.